Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01419639 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
A Phase 2 study of Neurofibromatosis Type II, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01419639 is a Phase 2 study of Neurofibromatosis Type II that has completed, run by NYU Langone Health. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01419639, a Phase 2 study of Neurofibromatosis Type II, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies whether Everolimus is efficacious in treating neurofibromatosis 2.
Conditions Studied
Interventions
- DRUG Everolimus (RAD001) , Afinitor®
Study Locations (1)
New York
- New York University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01419639
The ClinicalTrials.gov registry entry for NCT01419639 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neurofibromatosis Type II appearing as the primary indexed condition, and to 1 intervention - of which Everolimus (RAD001) , Afinitor® is the first listed.
NCT01419639 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01419639 about?
NCT01419639 is a clinical study titled "Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2". This trial studies whether Everolimus is efficacious in treating neurofibromatosis 2.
What is the current status of trial NCT01419639?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2011-10. Estimated completion is 2013-12.
What conditions does trial NCT01419639 study?
This clinical trial studies the following conditions: Neurofibromatosis Type II.
What interventions are being tested in trial NCT01419639?
The interventions under investigation include: Everolimus (RAD001) , Afinitor® (DRUG).
Who is sponsoring clinical trial NCT01419639?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01419639 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.